<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117523">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01723969</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-40CRC</org_study_id>
    <secondary_id>2012-003714-14</secondary_id>
    <nct_id>NCT01723969</nct_id>
  </id_info>
  <brief_title>Screening Platform for Clinical Trials in Advanced Colorectal Cancer</brief_title>
  <acronym>SPECTAcolor</acronym>
  <official_title>Screening Platform of the EORTC for Clinical Trials in Advanced Colorectal Cancer &quot;SPECTAcolor&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alliance Boots</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <authority>Germany: Ethik-Kommission bei der Landes√§rztekammer Rheinland-Pfalz</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EORTC GastroIntestinal Tract Cancer Group and the EORTC HeadQuarters wish to set up a
      European screening platform for advanced colo-rectal cancer (CRC) patients. The goal of this
      screening platform is to provide quick access to new drugs to patients by offering a new
      structure for clinical trials.

      Currently some of the  most challenging clinical questions arise from the molecular
      sub-division of CRC that would theoretically allow to inhibit the specific, altered pathways
      in the patients.

      A major problem for trials in this &quot;personalized medicine&quot; is that the low frequency of the
      different mutations requires a high effort for screening and identifying the patients.

      The EORTC CRC screening platform will hopefully offer a feasible and efficient way to
      characterize the patients on the molecular basis of their tumors and allow to offer them
      rapid and preferential  participation in clinical studies with new drugs targeted to their
      specific pathway alterations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Tumour markers assessment</measure>
    <time_frame>Within 1 week after patient registration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Five basic tumour markers will be tested: Kras, nras, braf, MSI and PKI3</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2600</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Advanced Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Colo-rectal cancer</arm_group_label>
    <description>Tumour markers testing in patients with advanced or metastatic colo-rectal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Tumour markers testing</intervention_name>
    <description>Tumour markers testing in patients advanced or metastatic colo-rectal cancer.</description>
    <arm_group_label>Colo-rectal cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      FFPE blocks of tumour tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced or metastatic colo-rectal cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Colo-rectal cancer (advanced or metastatic)

          -  Before patient registration, written informed consent must be given according to
             ICH/GCP, and national/local regulations.

        Exclusion Criteria:

          -  Absence of patient's consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michel Praet</last_name>
    <email>michel.praet@eortc.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>DE 01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gunnar Folprecht, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>DE 04205</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Florian Lordick, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-Universitaet Muenchen - Klinikum der Universitaet Muenchen - Campus Grosshadern</name>
      <address>
        <city>Muenchen</city>
        <zip>DE 81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dominik Modest, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volker Heinemann, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniken Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>DE 26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claus-Henning Koehne, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>ES 08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Josep Tabernero, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>ES 08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ramon Salazar, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud Roth</last_name>
      <phone>022-372-77-43</phone>
    </contact>
    <investigator>
      <last_name>Arnaud Roth, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>41-21-314-1111</phone>
    </contact>
    <investigator>
      <last_name>Anna Dorothea Wagner, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 22, 2014</lastchanged_date>
  <firstreceived_date>November 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
